Search | Clinical Trials Finder

Conditions: Acne Vulgaris
Interventions: Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Epidermolysis Bullosa Simplex
Interventions: TolaSure Topical Gel, Vehicle Topical Gel; Drug
Lead sponsor: BioMendics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Pain
Interventions: Ibuprofen 5% topical gel, Topical gel vehicle, Sodium lauryl sulfate 0.2%, Sodium chloride solution 0.9% (saline); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Carlstadt, New Jersey

Conditions: Severe Acne Vulgaris
Interventions: Adapalene BPO Gel associated with Doxycyline Hyclate, Vehicle Gel associated with Doxycycline Hyclate; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 28
States / cities: Oceanside, California • San Diego, California • Denver, Colorado + 25 more

Conditions: Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Interventions: CLE-400, Vehicle; Drug
Lead sponsor: Clexio Biosciences Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 13
States / cities: Bryant, Arkansas • Fremont, California • Coral Gables, Florida + 10 more

Conditions: Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Interventions: HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo; Drug
Lead sponsor: Hoth Therapeutics, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 9
States / cities: Irvine, California • Orange, California • Miami, Florida + 6 more

Conditions: Rosacea
Interventions: CLS001 (Omiganan), Vehicle; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 20
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Manhattan Beach, California + 17 more

Conditions: Atopic Dermatitis
Interventions: DMT210 Topical Gel, Vehicle Control; Drug
Lead sponsor: Dermata Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Houston, Texas • Norfolk, Virginia

Conditions: Actinic Keratosis
Interventions: GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 18 Years and older
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Fort Smith, Arkansas • San Diego, California • San Ramon, California + 13 more

Conditions: Genital Warts, Perianal Warts
Interventions: NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Fountain Valley, California • Lomita, California • San Diego, California + 11 more

Conditions: Dermatitis, Atopic, Pruritus
Interventions: ASN008, ASN008 Matching Vehicle; Drug · Other
Lead sponsor: Formation Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 27
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more

Conditions: Molluscum Contagiosum
Interventions: VBP-245 Topical Gel, Vehicle; Drug
Lead sponsor: Veloce BioPharma LLC; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Fort Washington, Pennsylvania • Greenville, South Carolina • Mt. Pleasant, South Carolina

Conditions: Painful Diabetic Neuropathy
Interventions: Placebo Gel, Clonidine Topical Gel (ARC-4558); Drug
Lead sponsor: Arcion Therapeutics Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Sacramento, California • Santa Monica, California + 13 more

Conditions: Acne Vulgaris
Interventions: BPX-01 1% Minocycline Topical Gel, BPX-01 2% Minocycline Topical Gel, BPX-01 Vehicle Topical Gel; Drug
Lead sponsor: BioPharmX, Inc.; Industry
Eligibility: 9 Years to 40 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Santa Monica, California • Coral Gables, Florida • Lake Mary, Florida + 12 more

Conditions: Neurofibromatosis 1, Cutaneous Neurofibroma
Interventions: NFX-179 Gel, Vehicle Gel; Drug
Lead sponsor: NFlection Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Fremont, California • New Brighton, Minnesota • Rochester, New York + 3 more

Conditions: Osteoarthritis of the Knee
Interventions: OLT1177 Gel, Placebo gel; Drug · Other
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: DeLand, Florida • South Miami, Florida • Raleigh, North Carolina

Conditions: Acne Vulgaris
Interventions: adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel); Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Fremont, California • Miami, Florida • Miramar, Florida + 5 more

Conditions: Foot Ulcer, Diabetic, Diabetic Foot
Interventions: NorLeu3-A(1-7) in a gel formulation; Drug
Lead sponsor: US Biotest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Tucson, Arizona • Castro Valley, California • San Diego, California + 8 more

Conditions: Rosacea
Interventions: CD07805/47 Gel, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Hot Springs, Arkansas • Miami Beach, Florida • Newnan, Georgia + 9 more

Conditions: Acne Vulgaris
Interventions: Adapalene/Benzoyl Peroxide, Adapalene Gel, 0.1%, Benzoyl Peroxide Gel 2.5%, Gel Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rosacea
Interventions: Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more

Conditions: Acne Vulgaris, Acne
Interventions: CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more

Conditions: Acne Vulgaris
Interventions: Olumacostat Glasaretil, Vehicle; Drug · Other
Lead sponsor: Dermira, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 28
States / cities: Mobile, Alabama • Encino, California • San Diego, California + 24 more

Conditions: Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions: RGN-137, Placebo; Drug
Lead sponsor: Lenus Therapeutics, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more

Search by objective public record fields.

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex

Ibuprofen 5% Topical Gel CIPT

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

DMT210 Topical Gel in the Treatment of Atopic Dermatitis

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum

Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa